Nonalcoholic Fatty Liver Disease

Young women with nonalcoholic fatty liver disease had higher testosterone levels, which led to a twofold higher risk for nonalcoholic steatohepatitis and fibrosis, according to study results.

Opioid use was more common in patients with nonalcoholic fatty liver disease with cirrhosis, higher BMI and psychiatric disease, according to a study published in Digestive Diseases.

Healio Gastroenterology presents some of the top stories from The Digital International Liver Congress 2020.

Compared with men, women had a significantly higher frequency of underlying nonalcoholic fatty liver disease and noncirrhotic hepatocellular carcinoma, according to data published in the American Journal of Gastroenterology.

Patients with non-alcoholic fatty liver disease are more likely to develop diabetes, according to a meta-analysis published in Gut.

Lean Asian patients with nonalcoholic fatty liver disease had significantly lower prevalence of cirrhosis, cardiovascular disease and metabolic abnormalities than lean non-Asian patients.

Vupanorsen, an investigational antisense therapy, reduced triglyceride levels at 6 months and demonstrated benefit on additional lipid parameters compared with placebo in patients with hypertriglyceridemia, diabetes and hepatic steatosis.

Machine learning may be a reasonable solution for screening for fatty liver in the general population in areas where more niche noninvasive tests are unavailable, according to a presenter at the Digital International Liver Congress.

In this exclusive video, Thomas Berg, MD, head of the section of hepatology at The University of Leipzig, discusses data presented at The Digital International Liver Congress on the role of non-alcoholic fatty liver disease in COVID-19 mortality risk.

Through an international registry presented at the Digital International Liver Congress, experts found COVID-19 in the presence of liver disease like non-alcoholic fatty liver disease or cirrhosis conferred a greater risk for mortality and morbidity.